tiprankstipranks
Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform
The Fly

Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in market cap over the past few weeks, creating an attractive entry point given that “a lot” is not priced into the stock at the moment, the analyst tells investors in a research note. Eli Lilly’s strong share performance in 2025 from GLP-1 volume growth remains underappreciated, and the firm also sees continued manufacturing efficiencies from legacy sites, Wolfe adds.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App